Influence of Chemotherapy on EGFR Mutation Status Among Patients With Non–Small-Cell Lung Cancer

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486

EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909530 · Cited by 5,525

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489

Erlotinib in Previously Treated Non–Small-Cell Lung Cancer

Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419

EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib

Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Mitsudomi, T., Morita, S., Yatabe, Y., Negoro, S., Okamoto, I., Tsurutani, J., Seto, T., Satouchi, M., Tada, H., Hirashima, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70364-x · Cited by 4,090

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

Zhou, C., Wu, Y.-L., Chen, G., Feng, J., Liu, X.-Q., Wang, C., Zhang, S., Wang, J., Zhou, S., Ren, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70184-x · Cited by 4,081

Liquid biopsy: monitoring cancer-genetics in the blood

Crowley, E. H., Nicolantonio, F. D., Loupakis, F., & Bardelli, A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.110 · Cited by 1,857

Biological and therapeutic impact of intratumor heterogeneity in cancer evolution

McGranahan, N., & Swanton, C. (2015) · Cancer Cell · doi:10.1016/j.ccell.2014.12.001 · Cited by 1,077

Artificial Intelligence in Cancer Research and Precision Medicine

Bhinder, B., Gilvary, C., Madhukar, N. S., & Elemento, O. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0090 · Cited by 781

The emerging role of cell-free DNA as a molecular marker for cancer management

Bronkhorst, A. J., Ungerer, V., & Holdenrieder, S. (2019) · Biomolecular Detection and Quantification · doi:10.1016/j.bdq.2019.100087 · Cited by 566

Gefitinib Versus Gefitinib Plus Pemetrexed and Carboplatin Chemotherapy in EGFR -Mutated Lung Cancer

Noronha, V., Patil, V., Joshi, A., Menon, N. S., Chougule, A., Mahajan, A., Janu, A., Purandare, N. C., Kumar, R., More, S. B., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.01154 · Cited by 427

Heterogeneity in Lung Cancer

de Sousa, V. M. L., & Carvalho, L. (2018) · Pathobiology · doi:10.1159/000487440 · Cited by 383

Non-invasive decision support for NSCLC treatment using PET/CT radiomics

Mu, W., Jiang, L., Zhang, J., Shi, Y., Gray, J. E., Tunali, I., Gao, C., Sun, Y., Tian, J., Zhao, X., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19116-x · Cited by 293

Radiomics and its emerging role in lung cancer research, imaging biomarkers and clinical management: State of the art

Lee, G., Lee, H. Y., Park, H., Schiebler, M. L., van Beek, E. J. R., Ohno, Y., Seo, J. B., & Leung, A. N. C. (2016) · European Journal of Radiology · doi:10.1016/j.ejrad.2016.09.005 · Cited by 281

Circulating Tumor DNA as Biomarkers for Cancer Detection

Han, X., Wang, J., & Sun, Y. (2017) · Genomics Proteomics & Bioinformatics · doi:10.1016/j.gpb.2016.12.004 · Cited by 246

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial

Karachaliou, N., Mayo-de las Casas, C., Queralt, C., de Aguirre, I., Melloni, B., Cardenal, F., Garcia-Gomez, R., Massuti, B., Sánchez, J. M., Porta, R., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2014.257 · Cited by 239

Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis

Luo, J., Shen, L., & Zheng, D. (2014) · Scientific Reports · doi:10.1038/srep06269 · Cited by 212

Highly Sensitive Droplet Digital PCR Method for Detection of EGFR-Activating Mutations in Plasma Cell–Free DNA from Patients with Advanced Non–Small Cell Lung Cancer

Zhu, G., Ye, X., Dong, Z., Lu, Y., Sun, Y., Liu, Y., McCormack, R., Gu, Y., & Liu, X. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.01.004 · Cited by 202

Circulating Tumor DNA Is Effective for the Detection of EGFR Mutation in Non–Small Cell Lung Cancer: A Meta-analysis

Qiu, M., Wang, J., Xu, Y., Ding, X., Li, M., Jiang, F., Xu, L., & Yin, R. H. (2014) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-14-0895 · Cited by 193

A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives

Russo, A., Franchina, T., Rita Ricciardi, G. R., Picone, A., Ferraro, G., Zanghì, M., Toscano, G., Giordano, A., & Adamo, V. (2015) · Oncotarget · doi:10.18632/oncotarget.4254 · Cited by 173

Mining whole-lung information by artificial intelligence for predicting EGFR genotype and targeted therapy response in lung cancer: a multicohort study

Wang, S., Yu, H., Gan, Y., Wu, Z., Li, E., Li, X., Cao, J., Zhu, Y., Wang, L., Deng, H., et al. (2022) · The Lancet Digital Health · doi:10.1016/s2589-7500(22)00024-3 · Cited by 182

Detection of EGFR mutations in plasma and biopsies from non-small cell lung cancer patients by allele-specific PCR assays

Weber, B., Meldgaard, P., Hager, H., Wu, L., Wei, W., Tsai, J., Khalil, A. A., Nexø, E., & Sørensen, B. S. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-294 · Cited by 154

Network Meta-Analysis of Erlotinib, Gefitinib, Afatinib and Icotinib in Patients with Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations

Liang, W., Wu, X., Fang, W., Zhao, Y., Yang, Y., Hu, Z., Xue, C., Zhang, J., Zhang, J., Ma, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085245 · Cited by 134

Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma

Cai, W., Lin, D., Wu, C., Li, X., Zhao, C., Zheng, L.-M., Chuai, S., Fei, K., Zhou, C., & Hirsch, F. R. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.8293 · Cited by 134

Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study

Lee, J. J.-K., Shin, J. Y., Kim, S., Lee, S., Park, C. C., Kim, J. Y., Koh, Y., Keam, B., Min, H. S., Kim, T. M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt127 · Cited by 130

Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: Re-analysis of the SATURN study

Mazières, J., Brugger, W., Cappuzzo, F., Middel, P., Frosch, A., Bāra, I., Klingelschmitt, G., & Klughammer, B. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.016 · Cited by 122

Clinical Significance of EML4-ALK Fusion Gene and Association with EGFR and KRAS Gene Mutations in 208 Chinese Patients with Non-Small Cell Lung Cancer

Li, Y., Li, Y., Yang, T., Wei, S., Wang, J., Wang, M., Wang, Y., Zhou, Q., Liu, H., & Chen, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0052093 · Cited by 115

A Comparison of EGFR Mutation Testing Methods in Lung Carcinoma: Direct Sequencing, Real-time PCR and Immunohistochemistry

Angulo, B., Conde, E., Suárez‐Gauthier, A., Plaza, C., Martínez, R., Redondo, P., Izquierdo, E., Rubio‐Viqueira, B., Paz-Ares, L. G., Hidalgo, M. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043842 · Cited by 101

Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer

Siena, S., Bianchi, A. S., García‐Carbonero, R., Karthaus, M., Smith, D. M., Tabernero, J. M., Cutsem, E. V., Guan, X., Boedigheimer, M. J., Ang, A. L., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx504 · Cited by 99

Quantitative image variables reflect the intratumoral pathologic heterogeneity of lung adenocarcinoma

Choi, E.-R., Lee, H. Y., Jeong, J. Y., Choi, Y., Kim, J., Bae, J., Lee, K. S., & Shim, Y. M. (2016) · Oncotarget · doi:10.18632/oncotarget.11693 · Cited by 91

Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small cell lung cancer based on epidermal growth factor receptor mutation status

Zhong, W., Yang, X., Yan, H., Zhang, X., Su, J., Chen, Z., Liao, R.-Q., Nie, Q., Dong, S., Zhou, Q. H., et al. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0151-3 · Cited by 91

Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer

Bai, H., Wang, Z., Wang, Y., Zhuo, M., Zhou, Q., Duan, J., Yang, L., Wu, M., An, T., Zhao, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054170 · Cited by 89

Tumour tissue sampling for lung cancer management in the era of personalised therapy: what is good enough for molecular testing?

Kim, L., & Tsao, M. (2014) · European Respiratory Journal · doi:10.1183/09031936.00197013 · Cited by 87

Role of circulating-tumor DNA analysis in non-small cell lung cancer

Jiang, T., Ren, S., & Zhou, C. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.09.013 · Cited by 84

Cross-Platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Non-Small Cell Lung Carcinoma Patient Plasma

Xu, T., Kang, X., You, X., Dai, L. X., Tian, D., Yan, W., Yang, Y., Xiong, H., Liang, Z., Zhao, G., et al. (2017) · Theranostics · doi:10.7150/thno.16558 · Cited by 82

Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer

Yang, X., Zhuo, M., Ye, X., Bai, H., Wang, Z., Sun, Y., Zhao, J., An, T., Duan, J., Wu, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8021 · Cited by 82

Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives

Chen, H., & Cheng, X. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s66502 · Cited by 81

Peripheral Blood for Epidermal Growth Factor Receptor Mutation Detection in Non-Small Cell Lung Cancer Patients

Li, X., Ren, R., Ren, S., Chen, X., Cai, W., Zhou, F., Zhang, Y., Su, C., Zhao, C., Li, J., et al. (2014) · Translational Oncology · doi:10.1016/j.tranon.2014.04.006 · Cited by 74

Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations

Li, X., Cai, W., Yang, G., Su, C., Ren, S., Zhao, C., Hu, R., Chen, X., Gao, G., Guo, Z., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.06.006 · Cited by 67

Overcoming drug resistance to receptor tyrosine kinase inhibitors: Learning from lung cancer

Kuwano, M., Sonoda, K., Murakami, Y., Watari, K., & Ono, M. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.002 · Cited by 66

Circulating DNA in diagnosis and monitoring EGFR gene mutations in advanced non-small cell lung cancer.

Bordi, P., Re, M. D., Danesi, R., & Tiseo, M. (2015) · PubMed Central · doi:10.3978/j.issn.2218-6751.2015.08.09 · Cited by 66

PIK3CA Mutational Status in Circulating Tumor Cells Can Change During Disease Recurrence or Progression in Patients with Breast Cancer

Markou, A. N., Farkona, S., Schiza, C., Efstathiou, T., Kounelis, S., Malamos, N., Georgoulias, V., & Lianidou, E. S. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0149 · Cited by 61

Cell-free circulating tumor DNA in plasma/serum of non-small cell lung cancer

Nie, K., Jia, Y., & Zhang, X. (2014) · Tumor Biology · doi:10.1007/s13277-014-2758-3 · Cited by 61

First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis

Holleman, M. S., van Tinteren, H., Groen, H. J. M., Al, M., & Groot, C. A. U. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s189438 · Cited by 62

Potential Resistance Mechanisms Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs)

Zhong, J., Li, L., Wang, Z., Bai, H., Gai, F., Duan, J., Zhao, J., Zhuo, M., Wang, Y., Wang, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.032 · Cited by 61

Epithelial phenotype as a predictive marker for response to EGFR-TKIs in non-small cell lung cancer patients with wild-type EGFR

Ren, S., Su, C., Wang, Z., Li, J., Fan, L., Li, B., Li, X., Zhao, C., Wu, C., Hou, L., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28925 · Cited by 53

Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancer

Qian, X., Liu, J., Sun, Y., Wang, M., HuaiDing, L., Luo, G., Liu, X., Xiong, C., Liu, J., Liu, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8684 · Cited by 52

Fool’s gold, lost treasures, and the randomized clinical trial

Stewart, D. J., & Kurzrock, R. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-193 · Cited by 51

Mixed Responses to Systemic Therapy Revealed Potential Genetic Heterogeneity and Poor Survival in Patients with Non-Small Cell Lung Cancer

Dong, Z., Zhai, H.-R., Hou, Q., Su, J., Liu, S., Yan, H., Li, Y.-S., Chen, Z., Zhong, W., & Wu, Y.-L. L. C. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0150 · Cited by 50

Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non–Small Cell Lung Cancer

Wan, R., Wang, Z., Lee, J. J., Wang, S., Li, Q., Tang, F., Wang, J., Sun, Y. L., Bai, H., Wang, D., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.05.011 · Cited by 47

Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications

Juan, Ó., & Popat, S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016687262 · Cited by 43

Tumour biomarkers—Tracing the molecular function and clinical implication

Lin, J., Ma, L., Zhang, D., Gao, J., Jin, Y., Han, Z., & Lin, D. (2019) · Cell Proliferation · doi:10.1111/cpr.12589 · Cited by 42

Favorable Prognostic Impact in Loss of TP53 and PIK3CA Mutations after Neoadjuvant Chemotherapy in Breast Cancer

Jiang, Y., Yu, K., Bao, J., Peng, W.-T., & Shao, Z. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0092 · Cited by 40

Understanding Mechanisms of Resistance in the Epithelial Growth Factor Receptor in Non-Small Cell Lung Cancer and the Role of Biopsy at Progression

Socinski, M. A., Villaruz, L. C., & Ross, J. S. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0285 · Cited by 40

Detection of EGFR Mutations by TaqMan Mutation Detection Assays Powered by Competitive Allele-Specific TaqMan PCR Technology

Roma, C., Esposito, C., Rachiglio, A. M., Pasquale, R., Iannaccone, A., Chicchinelli, N., Franco, R., Mancini, R., Pisconti, S., Luca, A. D., et al. (2013) · BioMed Research International · doi:10.1155/2013/385087 · Cited by 38

Major challenges related to tumor biological characteristics in accurate mutation detection of colorectal cancer by next-generation sequencing

Li, W., Qiu, T., Guo, L., & Ying, J. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.09.014 · Cited by 38

Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay

Guo, Q., Wang, L., Yu, W., Qiao, L., Zhao, M., Hu, X., Sun, Y., Ni, S., Xu, Y., & Lou, J. (2019) · Journal of Cancer · doi:10.7150/jca.31326 · Cited by 35

Impact of Bioinformatic Procedures in the Development and Translation of High-Throughput Molecular Classifiers in Oncology

Ferté, C., Trister, A. D., Huang, E. S., Bot, B. M., Guinney, J., Commo, F., Sieberts, S. K., André, F., Besse, B., Soria, J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3937 · Cited by 36

The emerging treatment landscape of advanced non-small cell lung cancer

Economopoulou, P., & Mountzios, G. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.07 · Cited by 36

Analysis of Intratumor Heterogeneity of EGFR Mutations in Mixed Type Lung Adenocarcinoma

Tomonaga, N., Nakamura, Y., Yamaguchi, H., Ikeda, T., Mizoguchi, K., Motoshima, K., Doi, S., Nakatomi, K., Iida, T., Hayashi, T., et al. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.04.005 · Cited by 35

Cytotoxic chemotherapy may overcome the development of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) therapy

Kanda, S., Horinouchi, H., Fujiwara, Y., Nokihara, H., Yamamoto, N., Sekine, I., Kunitoh, H., Kubota, K., Tamura, T., & Ohe, Y. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.06.016 · Cited by 34

Post surgery circulating free tumor DNA is a predictive biomarker for relapse of lung cancer

Hu, W., Yang, Y., Zhang, L., Yin, J., Huang, J., Huang, L., Gu, H., Jiang, G., & Fang, J. (2017) · Cancer Medicine · doi:10.1002/cam4.980 · Cited by 30

EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistance.

Remón, J., & Majem, M. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.10.14 · Cited by 29

Targeted Therapy Based on Tumor Genomic Analyses in Metastatic Urachal Carcinoma

Loh, K. P., Mondo, E. L., Hansen, E., Sievert, L., Fung, C., Sahasrabudhe, D. M., & Guancial, E. A. (2016) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2016.03.013 · Cited by 30

Epidermal growth factor receptor mutation in non-small-cell lung carcinomas: A retrospective analysis of 1036 lung cancer specimens from a network of tertiary cancer care centers in India

Veldore, V., Rao, R. M., Kakara, S., Pattanayak, S., Tejaswi, R., Sahoo, R., Venkataswamy, E., Prabhudesai, S., Krishnamoorthy, N., Tejaswini, B. N., et al. (2013) · Indian Journal of Cancer · doi:10.4103/0019-509x.117013 · Cited by 29

Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma

Hollander, P., Amini, R., Ginman, B., Molin, D. L., Enblad, G., & Glimelius, I. C. (2018) · PLoS ONE · doi:10.1371/journal.pone.0204870 · Cited by 29

Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay

Hou, H., Yang, X., Zhang, J., Zhang, Z., Xu, X., Zhang, X., Zhang, C., Liu, D., Yan, W., Zhu, H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14962-0 · Cited by 28

Autoimmune response to PARP and BRCA1/BRCA2 in cancer

Zhu, Q., Han, S.-X., Zhou, C.-Y., Cai, M.-J., Dai, L.-P., & Zhang, J.-Y. (2015) · Oncotarget · doi:10.18632/oncotarget.3428 · Cited by 27

Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study

Tan, X., Li, Y., Wang, S., Xia, H., Meng, R., Xu, J., Duan, Y., Li, Y., Yang, G., Ma, Y., et al. (2022) · Respiratory Research · doi:10.1186/s12931-022-02053-2 · Cited by 30

Saliva‐derived cfDNA is applicable for EGFR mutation detection but not for quantitation analysis in non‐small cell lung cancer

Ding, S., Song, X., Geng, X., Liu, L., Ma, H., Wang, X., Wei, L., Xie, L., & Song, X. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13178 · Cited by 27

Results of the First Italian External Quality Assurance Scheme for Somatic EGFR Mutation Testing in Non–Small-Cell Lung Cancer

Normanno, N., Pinto, C., Taddei, G., Gambacorta, M., Castiglione, F., Barberis, M. C. P., Clemente, C., & Marchetti, A. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31828c2b08 · Cited by 26

Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer

Asami, K. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.646 · Cited by 25

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study

Kim, I. A., Lee, J. S., Kim, H. J., Kim, W. S., & Lee, K. Y. (2018) · BMC Cancer · doi:10.1186/s12885-018-4691-0 · Cited by 25

EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: a meta-analysis

Zhang, Q., Dai, H.-H., Dong, H.-Y., Sun, C.-T., Yang, Z., & Han, J.-Q. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.06.011 · Cited by 25

Clinical value of ALU concentration and integrity index for the early diagnosis of ovarian cancer: A retrospective cohort trial

Zhang, R., Pu, W., Zhang, S., Chen, L., Zhu, W., Li, X., Xing, C., & Li, K. (2018) · PLoS ONE · doi:10.1371/journal.pone.0191756 · Cited by 25

Mutation abundance affects the therapeutic efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma: A retrospective analysis

Wang, H., Zhang, M., Tang, W., Ma, J., Wei, B., Niu, Y., Zhang, G., Li, P., Yan, X., & Ma, Z. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1450115 · Cited by 24

Technical and Regulatory Considerations for Taking Liquid Biopsy to the Clinic: Validation of the JAX PlasmaMonitor TM Assay

Sisson, B., Uvalic, J., Kelly, K., Selvam, P., Hesse, A., Ananda, G., Chandok, H., Bergeron, D., Holinka, L., & Reddi, H. V. (2019) · Biomarker Insights · doi:10.1177/1177271919826545 · Cited by 24

GMILT: A Novel Transformer Network That Can Noninvasively Predict EGFR Mutation Status

Zhao, W., Chen, W., Li, G., Lei, D., Yang, J., Chen, Y., Jiang, Y., Wu, J., Ni, B., Sun, Y., et al. (2022) · IEEE Transactions on Neural Networks and Learning Systems · doi:10.1109/tnnls.2022.3190671 · Cited by 26

Intratumoral Heterogeneity in Lung Cancer

Lv, X., Mao, Z., Sun, X., & Liu, B. (2023) · Cancers · doi:10.3390/cancers15102709 · Cited by 26

AI-based pipeline for early screening of lung cancer: integrating radiology, clinical, and genomics data

Batra, U., Nathany, S., Nath, S. K., Jose, J. T., Sharma, T., Preeti, P., Pasricha, S., Sharma, M., Arambam, N., Khanna, V., et al. (2024) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2024.100352 · Cited by 24

Beyond EGFR TKI in EGFR-mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome

Remón, J., Morán, T., Reguart, N., Majem, M., Carcereny, E., & LIANES, P. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.03.006 · Cited by 22

Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291)

Saad, N., Poudel, A., Basnet, A., & Gajra, A. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s100650 · Cited by 23

Target Therapy in Lung Cancer

Cafarotti, S., Lococo, F., Frösch, P., Zappa, F., & Dutly, A. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24223-1_6 · Cited by 21

Therapeutic bronchoscopy in the era of genotype directed lung cancer management

Mohan, A., Harris, K. N., Bowling, M., Brown, C., & Hohenforst‐Schmidt, W. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.08.14 · Cited by 22

Transfer learning–based PET/CT three-dimensional convolutional neural network fusion of image and clinical information for prediction of EGFR mutation in lung adenocarcinoma

Shao, X., Ge, X., Gao, J., Niu, R., Shi, Y., Shao, X., Jiang, Z., Li, R., & Wang, Y. (2024) · BMC Medical Imaging · doi:10.1186/s12880-024-01232-5 · Cited by 21

Detection of EGFR Mutations in the Plasma of Patients with Lung Adenocarcinoma for Real-Time Monitoring of Therapeutic Response to Tyrosine Kinase Inhibitors?

Marcq, M., Vallée, A., Bizieux, A., & Denis, M. G. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000134 · Cited by 20

Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma

He, Y., Wang, Y., Boyle, T. A., Ren, S., Chan, D., Rivard, C. J., Li, X., Li, J., Zhou, C., & Hirsch, F. R. (2016) · Medical Science Monitor · doi:10.12659/msm.896607 · Cited by 20

Micropapillary: A component more likely to harbour heterogeneous EGFR mutations in lung adenocarcinomas

Cai, Y., Dong, Y., Wu, H., Liu, Z.-C., Zhou, L.-J., Su, D., Chen, X.-J., Zhang, L., & Zhao, Y. (2016) · Scientific Reports · doi:10.1038/srep23755 · Cited by 20

Liquid biopsy for lung cancer immunotherapy (Review)

Cai, L., & Wang, J. (2019) · Oncology Letters · doi:10.3892/ol.2019.10166 · Cited by 19

Investigating intratumour heterogeneity by single-cell sequencing

Ren, S., Qu, M., & Ying-hao, S. U. N. (2013) · Asian Journal of Andrology · doi:10.1038/aja.2013.106 · Cited by 18

Transbronchoscopic patient biopsy-derived xenografts as a preclinical model to explore chemorefractory-associated pathways and biomarkers for small-cell lung cancer

Wang, Z., Fu, S., Zhao, J., Zhao, W., Shen, Z., Wang, D., Duan, J., Bai, H., Wan, R., Yu, J., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.014 · Cited by 18

Impact of EGFR mutation status on tumor response and progression free survival after first-line chemotherapy in patients with advanced non-small-cell lung cancer: a meta-analysis.

Liang, W., Zhang, Y., Kang, S., Pan, H., Shao, W., Deng, Q., Shi, X., Wang, W., & He, J. (2014) · PubMed Central · doi:10.3978/j.issn.2072-1439.2014.07.33 · Cited by 18

Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC: A Meta-Analysis

OuYang, P., Su, Z. Z., Mao, Y., Deng, W., & Xie, F. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079000 · Cited by 18

EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature

Yang, Y., Zhang, B., Li, R., Liu, B., & Wang, L. (2016) · Oncology Letters · doi:10.3892/ol.2016.4409 · Cited by 17

Efficacy and safety of icotinib in Chinese patients with advanced nonsmall cell lung cancer after failure of chemotherapy

Shao, L., Zhang, B., He, C., Lin, B., Song, Z., Lou, G., Yu, X., & Zhang, Y. (2014) · Chinese Medical Journal · doi:10.3760/cma.j.issn.0366-6999.20131290 · Cited by 17

Circulating tumor DNA (ctDNA) in the era of personalized cancer therapy

Khatami, F., & Tavangar, S. M. (2018) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-018-0334-x · Cited by 18

Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting

Wang, Q., Gao, W., Gao, F., Jin, S., Qu, T., Lin, F., Zhang, C., Zhang, J., Zhang, Z., Chen, L., et al. (2021) · BMC Cancer · doi:10.1186/s12885-021-08291-9 · Cited by 15

Adjuvant Therapy of Resected Non-small Cell Lung Cancer: can We Move Forward?

Buffoni, L., Vavalà, T., & Novello, S. (2016) · Current Treatment Options in Oncology · doi:10.1007/s11864-016-0429-x · Cited by 17

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors As Adjuvant Therapy in Completely Resected Non–Small-Cell Lung Cancer

Novello, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.7587 · Cited by 17

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma

Tseng, J., Yang, T., Chen, K., Hsu, K.-H., Yu, C., Liao, W., Tsai, C., Tsai, M.-H., Yu, S., Su, K., et al. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s62639 · Cited by 16

Phase II Trial of Erlotinib for Japanese Patients With Previously Treated Non-small-cell Lung Cancer Harboring EGFR Mutations: Results of Lung Oncology Group in Kyushu (LOGiK0803)

Yamada, K., Takayama, K., Kawakami, S., Saruwatari, K., Morinaga, R., Harada, T., Sueoka‐Aragane, N., Nagata, S., Kishimoto, J., Nakanishi, Y., et al. (2013) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyt056 · Cited by 16

Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer

Li, H., Zhang, X., Cao, J., Su, P., Lian, J., Song, X., Yang, W., Han, S., Xi, Y., & Wang, Y. (2015) · Tumor Biology · doi:10.1007/s13277-015-3653-2 · Cited by 16

Analysis of EGFR mutation status in tissue and plasma for predicting response to EGFR-TKIs in advanced non-small-cell lung cancer

Wang, Y., Duan, J., Chen, H., Bai, H., An, T., Zhao, J., Wang, Z., Zhuo, M., Wang, S., & Wang, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.5740 · Cited by 16

Adjuvant Therapy Reduces the Benefit of Palliative Treatment in Disseminated Breast Cancer - Own Findings and Review of the Literature

Kleeberg, U. R., Fink, M. K., Tessen, H.-W., Nennecke, A., Hentschel, S., & Bartels, S. (2013) · Oncology Research and Treatment · doi:10.1159/000351253 · Cited by 16

The use of mutation-specific antibodies in predicting the effect of EGFR-TKIs in patients with non-small-cell lung cancer

Zhao, J., Wang, X., Xue, L., Xu, N., Ye, X., Zeng, H., Lu, S., Huang, J., Akesu, S., Xu, C., et al. (2014) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-014-1618-2 · Cited by 15

Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations

Masuda, T., Imai, H., Kuwako, T., Miura, Y., Yoshino, R., Kaira, K., Shimizu, K., Sunaga, N., Tomizawa, Y., Ishihara, S., et al. (2015) · Clinical & Translational Oncology · doi:10.1007/s12094-015-1297-8 · Cited by 16

Effect of chemotherapy on EGFR mutation status in Chinese non-small cell lung cancer patients.

Wang, J., Bai, H., Zhao, J., Wang, Z., Zhuo, M., Wu, M., Duan, J., & Wang, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.e18031 · Cited by 2

Influence of chemotherapy on EGFR mutation status.

Luo, Y., & Chen, Y. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2013.10.12 · Cited by 12

Chemotherapy influence EGFR mutation status for Chinese patients with regionally advanced non-small cell lung cancer.

Wang, J., Chen, K., Bai, H., Zhao, J., Wang, Z., Zhuo, M., An, T., Duan, J., Yang, L., Wu, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.7031 · Cited by 4

The Impact of Chemotherapy on EGFR Mutation Status in Non-Small-Cell Lung Cancer: A Meta-Analysis

Shi, X., Huang, F., Chen, A. M., Wu, Z., Huang, Q., Liang, Y., Zhou, Q., Mo, H., Li, X., & Zhang, J. (2017) · Open Journal of Genetics · doi:10.4236/ojgen.2017.74010 · Cited by 1

Longitudinal evaluation of EGFR mutation in plasma for non-small cell lung cancer patients with front-line chemotherapy

Hua, B., Zhao, J., Wang, S. H., Yang, L., Duan, J. C., Wu, M. N., & Wang, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.8099 · Cited by 1